Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062152 · ClinicalTrials.gov registry record · Phase 1
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
A Phase 1 study, sponsored by Telik.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01062152 is a Phase 1 study that has completed, run by Telik. The registered enrollment target is 19 participants.
The verdict
NCT01062152, a Phase 1 study, has completed, sponsored by Telik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is an open label, multicenter Phase 1 dose escalation study evaluating five doses of ezatiostat in combination with lenalidomide in patients with non-del(5q) low to intermediate 1 risk MDS. The HI-E, HI-N, HI-P rates \[by International Working Group (IWG) 2006 criteria\] and safety of each treatment group will be evaluated to select the optimal dose of ezatiostat in combination with lenalidomide for future studies.
Interventions
- DRUG Lenalidomide (Revlimid®)
- DRUG Ezatiostat Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062152
The ClinicalTrials.gov registry entry for NCT01062152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telik, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide (Revlimid®) is the first listed.
NCT01062152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01062152 about?
NCT01062152 is a clinical study titled "Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)". This is an open label, multicenter Phase 1 dose escalation study evaluating five doses of ezatiostat in combination with lenalidomide in patients with non-del(5q) low to intermediate 1 risk MDS. The HI-E, HI-N, HI-P rates \[by International Working Group (IWG) 2006 criteria\] and safety of each trea...
What is the current status of trial NCT01062152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2009-11. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01062152?
The interventions under investigation include: Lenalidomide (Revlimid®) (DRUG), Ezatiostat Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01062152?
This trial is sponsored by Telik, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.